1. Raben M (1954) Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 2:901–903
2. Tillman V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibrige MS, Wales JK, Clayton P (2000) Monitoring serum IGF-I, IGFBP3, IGF-I/IGFBP3 ratio and leptin during growth hormone treatment for disordered growth. Clin Endocrinol 53:329–336
3. Mandel S, Moreland E, Nichols V, Hanna C, Lafranchi S (1995) Changes in insulin-like growth factor I (IGF-I), IGF binding protein 3 (IGFBP3), growth hormone binding protein, erythrocyte IGF-I receptors ad growth rate during GH treatment. J Clin Endocrinol Metab 80:190–194
4. Kristom B, Jansson C, Rosberg S, Albertsson-Wikland K (1997) Growth response to GH treatment relates to serum insulin like growth factor I (IGF-I) and IGF-binding protein 3 in short children with various growth hormone secretion capacities. J Clin Endocrinol Metab 82:2889–2898
5. Das U, Whatmore AJ, Khosravi J, Wales JKH, Butler G, Kibirige MS, Diamandi A, Jones J, Patel L, Hall CM, Price DA (2003) Clayton PE IGF-I and IGF-binding protein-3 measurements on filter paper blood spots in children and adolescents on GH treatment: use in monitoring and as markers of growth performance. Eur J Endocrinol 149:179–185